Wall Street analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings per share (EPS) of ($0.81) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Acorda Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.02) and the highest estimate coming in at ($0.55). Acorda Therapeutics posted earnings per share of $0.14 in the same quarter last year, which would indicate a negative year over year growth rate of 678.6%. The company is scheduled to report its next quarterly earnings results on Wednesday, May 1st.
According to Zacks, analysts expect that Acorda Therapeutics will report full year earnings of ($3.83) per share for the current year, with EPS estimates ranging from ($4.95) to ($2.83). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.78) per share, with EPS estimates ranging from ($4.31) to ($1.73). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, February 14th. The biopharmaceutical company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $1.64. The company had revenue of $69.20 million for the quarter, compared to analyst estimates of $48.12 million. Acorda Therapeutics had a return on equity of 12.98% and a net margin of 7.14%. The business’s quarterly revenue was down 63.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.61 earnings per share.
ACOR has been the subject of several recent research reports. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Acorda Therapeutics in a research note on Wednesday, December 26th. BidaskClub raised shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research lowered shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 22nd. Oppenheimer set a $18.00 target price on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Wednesday, January 2nd. Finally, Cantor Fitzgerald set a $32.00 target price on shares of Acorda Therapeutics and gave the stock a “hold acor” rating in a report on Monday, December 24th. Four research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $22.56.
Shares of ACOR traded up $0.34 during mid-day trading on Friday, hitting $15.08. 1,461,641 shares of the company’s stock were exchanged, compared to its average volume of 866,307. Acorda Therapeutics has a fifty-two week low of $12.55 and a fifty-two week high of $36.35. The company has a market capitalization of $614.92 million, a price-to-earnings ratio of 8.29 and a beta of 1.66. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.56 and a current ratio of 3.77.
In other news, major shareholder Scopia Capital Management Lp sold 225,000 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $20.51, for a total value of $4,614,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ron Cohen sold 3,620 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $20.60, for a total value of $74,572.00. Following the completion of the transaction, the chief executive officer now directly owns 487,554 shares of the company’s stock, valued at approximately $10,043,612.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,472,078 shares of company stock worth $25,067,727. Corporate insiders own 7.80% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its position in Acorda Therapeutics by 100.8% during the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,062 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in Acorda Therapeutics during the 4th quarter valued at approximately $44,000. NumerixS Investment Technologies Inc acquired a new stake in Acorda Therapeutics during the 4th quarter valued at approximately $77,000. Pacer Advisors Inc. acquired a new stake in Acorda Therapeutics during the 3rd quarter valued at approximately $110,000. Finally, Schroder Investment Management Group acquired a new stake in Acorda Therapeutics during the 3rd quarter valued at approximately $112,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
Recommended Story: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.